{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T21:17:22Z","timestamp":1773955042761,"version":"3.50.1"},"reference-count":45,"publisher":"Baishideng Publishing Group Inc.","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJG"],"published-print":{"date-parts":[[2004]]},"DOI":"10.3748\/wjg.v10.i6.894","type":"journal-article","created":{"date-parts":[[2017,10,30]],"date-time":"2017-10-30T04:09:44Z","timestamp":1509336584000},"page":"894","source":"Crossref","is-referenced-by-count":83,"title":["Fenofibrate for patients with asymptomatic primary biliary cirrhosis"],"prefix":"10.3748","volume":"10","author":[{"given":"Kazufumi","family":"Dohmen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Mizuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Nakamuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Shimohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyosuke","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199405123301903"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1053\/bega.2000.0107"},{"key":"ref3","unstructured":"Combes B, Carithers RL, Maddrey WC, Lin D, McDonald MF, Wheeler DE, Eigenbrodt EH, Mu\u00f1oz SJ, Rubin R, Garcia-Tsao G. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995;22:759-766."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/gut.36.6.935"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/gut.46.1.121"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(03)00006-0"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Jahn CE, Schaefer EJ, Taam LA, Hoofnagle JH, Lindgren FT, Albers JJ, Jones EA, Brewer HB. Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification. Gastroenterology 1985;89:1266-1278.","DOI":"10.1016\/0016-5085(85)90642-0"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(02)00006-5"},{"key":"ref9","unstructured":"Kurihara T, Yanagisawa A, Kitamura Y, Itabashi K, Arita Y, Tsuchiya M, Akimoto M, Ishiguro H, Hashimoto H, Maeda A. Effect of bezafibrate in patients with PBC. Rhinsho Iyaku 1997;13:4255-4258."},{"key":"ref10","unstructured":"Fukuo Y, Tada N, Yamamoto K. Study of efficacy of bezafibrate for PBC. Rinsho Seijinbyo 1999;29:1367–1372."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6346(99)00033-9"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.01667.x"},{"key":"ref13","unstructured":"Miyaguchi S, Ebinuma H, Imaeda H, Nitta Y, Watanabe T, Saito H, Ishii H. A novel treatment for refractory primary biliary cirrhosis. Hepatogastroenterology 2000;47:1518-1521."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.03220.x"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05645.x"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1210\/mend.11.6.0007"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/384039a0"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Chianale J, Vollrath V, Wielandt AM, Amigo L, Rigotti A, Nervi F, Gonzalez S, Andrade L, Pizarro M, Accatino L. Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse. Biochem J 1996;314:781-786.","DOI":"10.1042\/bj3140781"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05944.x"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2957\/kanzo.42.664"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S0270-9139(03)80786-3"},{"key":"ref22","unstructured":"Culp KS, Fleming CR, Duffy J, Baldus WP, Dickson ER. Autoimmune associations in primary biliary cirrhosis. Mayo Clin Proc 1982;57:365-370."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.31.289"},{"key":"ref24","unstructured":"Lindor KD, Dickson ER. Primary biliary cirrhosis. In Schiff's Diseases of the Liver, Eighth ed. Lippin Cott Raevan Publishers, Philadelphia 1999;679-692."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2000.8090"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2001.02614.x"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1023\/A:1013292210036"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199005173222003"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198504183121602"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07173.x"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70403-8"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07182.x"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1021\/jm990554g"},{"key":"ref34","unstructured":"Hata Y, Goto Y, Itakura H, Nakaya N, Saito Y. Clinical evalua-tion of fenofibrate (GRS-001) on hyperlipidemia –Double-blind study with bezafibrate. Ronen Igaku 1995;33:765-822."},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1136\/gut.51.2.265"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(92)80734-X"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 1996;37:907-925.","DOI":"10.1016\/S0022-2275(20)42003-6"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118118"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1038\/31701"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.99.24.3125"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Betz M, Fox BS. Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J Immunol 1991;146:108-113.","DOI":"10.4049\/jimmunol.146.1.108"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04209-4"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4274(98)00042-3"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1006\/taap.2002.9538"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(02)00129-0"}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v10\/i6\/894.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T18:50:57Z","timestamp":1693162257000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v10\/i6\/894.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004]]}},"URL":"https:\/\/doi.org\/10.3748\/wjg.v10.i6.894","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2004]]}}}